May 2025 Corporate Overview Exhibit 99.2

2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our clinical development plans and timelines and the initial safety and efficacy profiles of CNTY-101 are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our dependence on the success of our lead product candidate, CNTY-101; our ability to progress CNTY-101 through clinical development; our ability to meet development milestones on anticipated timelines; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials; our ability to obtain clearance of our future IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of geopolitical issues, trade disputes and tariffs, banking instability and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; our ability to recruit and maintain key members of management and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Estimated cash runway into 4Q26; re-allocating resources to enable key value milestones Enhanced preclinical pipeline and platform aiming to expand and multiply cell therapy value • Four potentially transformative programs engineered with industry-leading Allo-Evasion ed w on 5.0 • Leading programs focus on iPSC-HIVMZIHƄXYREFPIƅ'('(»¼8GIPPW • Selective expansion to non-immune effector cells in high impact diseases Estimated c to enable k Enhanced prec and multiply c • Four potentially t programs engine leading Allo-Evas Enhanced Preclinical Pipeline Concentrated Clinical Focus Resourcing for Value Concentrating clinical focus with CNTY-101 on autoimmune disorders with transformational potential • Unique profile of CD19-targeting iNK cell product engineered with Allo-Evasion e pro on with clinical data from R/R NHL reinforcing potential in autoimmune disorders • Expansion of Phase 1 CALiPSO-1 trial in US and EU with CARAMEL IIT expected to commence in mid-2025 Century Therapeutics: Clear focus on transformational value with unique iPSC-derived cell therapies GOAL: Expand and enhance cell therapy value • Ended 25Q1 with cash, cash equivalents, and investments of $185.8M • CNTY-308 DE T cell program expected to enter IND-enabling stage in mid-2025 • CNTY-101 autoimmune clinical data expected in 2025

4 Clear differentiation from other allogeneic cell therapies with pathway to antibody-like scale Century’s ability to create multiple iPSC-derived cell types incorporating Allo-Evasion ability on stands apart from other allogeneic cell therapy approaches Engineerability • Control of differentiation to multiple cell types • Nearly unlimited genetic editing capacity due to infinite replicative capacity Reproducibility • Fully characterized single cell clones form master cell bank (MCB) • Deep understanding of cell function and safety Profitable Scalability • Large batch sizes with batch-to-batch consistency • Pathway to significantly reduced COGS similar to antibody therapies • Expansion from a single-clone MCB decreases risk of cell exhaustion Allogeneic Allo-Evasion iPSCs Off-the-shelf therapies Potential for improved time-to-treatment Broad availability Manufacturing dependability Enables potential for persistence and re-dosing of therapy Engineering for immune evasion from: • Native T-cells and NK-cells • Antibody immunity 4